newsfilter
← Latest News
GlobeNewswire·

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory